These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 28553565)
1. Overview of FDA's Expanded Access Program for Investigational Drugs. Jarow JP; Lurie P; Ikenberry SC; Lemery S Ther Innov Regul Sci; 2017 Mar; 51(2):177-179. PubMed ID: 28553565 [TBL] [Abstract][Full Text] [Related]
2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related]
3. Oncology Expanded Access and FDA's Project Facilitate. Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259 [TBL] [Abstract][Full Text] [Related]
4. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety. Jarow JP; Lemery S; Bugin K; Lowy N Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566 [TBL] [Abstract][Full Text] [Related]
5. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs. Puthumana J; Miller JE; Kim J; Ross JS JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072 [TBL] [Abstract][Full Text] [Related]
6. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. Speers MA Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253 [TBL] [Abstract][Full Text] [Related]
7. Single-patient expanded access: A primer for pharmacists. Smith AJF; Redic KA Am J Health Syst Pharm; 2022 Nov; 79(23):2118-2127. PubMed ID: 36056791 [TBL] [Abstract][Full Text] [Related]
8. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period. Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324 [TBL] [Abstract][Full Text] [Related]
9. Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies. Van Norman GA JACC Basic Transl Sci; 2018 Jun; 3(3):403-414. PubMed ID: 30062226 [TBL] [Abstract][Full Text] [Related]
10. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. Bunnik EM; Aarts N BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313 [TBL] [Abstract][Full Text] [Related]
11. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs. Chapman CR; Eckman J; Bateman-House AS Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412 [TBL] [Abstract][Full Text] [Related]
13. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients. Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080 [TBL] [Abstract][Full Text] [Related]
14. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try". Van Norman GA JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214 [TBL] [Abstract][Full Text] [Related]
16. Taking AIM at serious illness: implementing an access to investigational medicines expanded access program. Joly MM; Edwards TL; Jerome RN; Mainor A; Bernard GR; Pulley JM Front Med (Lausanne); 2023; 10():1287449. PubMed ID: 37877021 [TBL] [Abstract][Full Text] [Related]
17. Patient advocacy organizations' information for patients on pre-approval access to investigational treatments. Folkers KM; Leone S; Caplan A BMC Res Notes; 2019 Oct; 12(1):706. PubMed ID: 31661023 [TBL] [Abstract][Full Text] [Related]
18. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment. Roller ST; Pippins RR; Ngai JW Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646 [TBL] [Abstract][Full Text] [Related]
19. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs. Gould P; Salam T; Kimberly L; Bateman-House A; Fernandez Lynch H JAMA Netw Open; 2022 Nov; 5(11):e2239766. PubMed ID: 36318206 [TBL] [Abstract][Full Text] [Related]
20. Understanding the Right to Try Act. Agarwal R; Saltz LB Clin Cancer Res; 2020 Jan; 26(2):340-343. PubMed ID: 31666248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]